BR112016020101A2 - - Google Patents

Info

Publication number
BR112016020101A2
BR112016020101A2 BR112016020101A BR112016020101A BR112016020101A2 BR 112016020101 A2 BR112016020101 A2 BR 112016020101A2 BR 112016020101 A BR112016020101 A BR 112016020101A BR 112016020101 A BR112016020101 A BR 112016020101A BR 112016020101 A2 BR112016020101 A2 BR 112016020101A2
Authority
BR
Brazil
Application number
BR112016020101A
Other languages
Portuguese (pt)
Other versions
BR112016020101B1 (pt
BR112016020101A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016020101A2 publication Critical patent/BR112016020101A2/pt
Publication of BR112016020101A8 publication Critical patent/BR112016020101A8/pt
Publication of BR112016020101B1 publication Critical patent/BR112016020101B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112016020101-9A 2014-03-31 2015-03-30 Composição farmacêutica sólida, composição farmacêutica liofilizada, método para a preparação de uma composição farmacêutica liofilizada sólida, método para a preparação de uma solução injetável e uso da composição farmacêutica BR112016020101B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP14162727.3 2014-03-31
PCT/EP2015/056824 WO2015150294A1 (en) 2014-03-31 2015-03-30 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Publications (3)

Publication Number Publication Date
BR112016020101A2 true BR112016020101A2 (enExample) 2017-07-15
BR112016020101A8 BR112016020101A8 (pt) 2021-06-29
BR112016020101B1 BR112016020101B1 (pt) 2023-05-30

Family

ID=

Also Published As

Publication number Publication date
IL248090B (en) 2019-10-31
CY1117881T1 (el) 2018-03-07
HRP20160802T1 (hr) 2016-08-12
MX377919B (es) 2025-03-10
US12458644B2 (en) 2025-11-04
PH12016501519A1 (en) 2017-02-06
MY180844A (en) 2020-12-10
US11717522B2 (en) 2023-08-08
US20260048056A1 (en) 2026-02-19
JP7178731B2 (ja) 2022-11-28
US20170296543A1 (en) 2017-10-19
JP2021105062A (ja) 2021-07-26
IL248090A0 (en) 2016-11-30
HK1213195A1 (en) 2016-06-30
EP2926805A1 (en) 2015-10-07
AU2015239736B2 (en) 2020-03-26
SG11201606151SA (en) 2016-08-30
JP6552515B2 (ja) 2019-07-31
US20220031703A9 (en) 2022-02-03
US10016431B2 (en) 2018-07-10
WO2015150294A1 (en) 2015-10-08
JP2019194227A (ja) 2019-11-07
RU2694368C2 (ru) 2019-07-12
PL2926805T3 (pl) 2016-12-30
CN106572976A (zh) 2017-04-19
JP6879582B2 (ja) 2021-06-02
SMT201600246B (it) 2016-08-31
US20230355630A1 (en) 2023-11-09
US9895372B2 (en) 2018-02-20
ES2586945T3 (es) 2016-10-19
AU2015239736A1 (en) 2016-08-11
SI2926805T1 (sl) 2016-09-30
RS54973B1 (sr) 2016-11-30
US20210137927A1 (en) 2021-05-13
US10493075B2 (en) 2019-12-03
KR102374500B1 (ko) 2022-03-15
US20170112836A1 (en) 2017-04-27
PT2926805T (pt) 2016-07-15
DK2926805T3 (en) 2016-07-25
CA2938267C (en) 2023-05-09
JP2017509623A (ja) 2017-04-06
CN113521017A (zh) 2021-10-22
CA2938267A1 (en) 2015-10-08
PE20161253A1 (es) 2016-11-13
US10925877B2 (en) 2021-02-23
RU2016141449A3 (enExample) 2018-12-14
HUE030221T2 (en) 2017-04-28
NZ722455A (en) 2022-03-25
AU2020203880B2 (en) 2022-03-31
CL2016002463A1 (es) 2017-01-27
RU2016141449A (ru) 2018-05-07
MX2016012784A (es) 2017-04-25
AU2020203880A1 (en) 2020-07-02
SA516371933B1 (ar) 2019-04-14
US20180289714A1 (en) 2018-10-11
BR112016020101A8 (pt) 2021-06-29
US20200046710A1 (en) 2020-02-13
KR20160138406A (ko) 2016-12-05
ZA201605271B (en) 2017-08-30
EP2926805B1 (en) 2016-05-18
EP3125864A1 (en) 2017-02-08
PH12016501519B1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
BR112016017664A2 (enExample)
BR112016017979A2 (enExample)
BR112016016761A2 (enExample)
BR112016015519A2 (enExample)
BR112016015890A2 (enExample)
BR112016003131A2 (enExample)
BR112016016490A2 (enExample)
BR112016016546A2 (enExample)
BR112016014949A2 (enExample)
BR112016018264A2 (enExample)
BR112016017103A2 (enExample)
BR112016017031A2 (enExample)
BR112016016924A2 (enExample)
BR112016016421A2 (enExample)
BR112016016106A2 (enExample)
BR112016012568A2 (enExample)
BR112016016558A2 (enExample)
BR112016015798A2 (enExample)
BR112016017960A2 (enExample)
BR112016015915A2 (enExample)
BR112016018252A2 (enExample)
BR112016016389A2 (enExample)
BR112016016468A2 (enExample)
BR112016017356A2 (enExample)
BR112016016459A2 (enExample)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2015, OBSERVADAS AS CONDICOES LEGAIS